Topical or oral JAK inhibitors, such as ruxolitinib and tofacitinib, have shown promise in classic vitiligo by suppressing the IFN-γ–STAT1–CXCL10 axis and may hold potential for the treatment of VLD. The gene discussed is STAT1; the disease is vitiligo.